[Application and Research Progress of Selinexor in Hematologic Tumors Other Than Multiple Myeloma --Review]

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Exportin-1 (XPO1) is a key transporter protein implicated in various cellular functions.
• Selinexor is the first-in-class XPO1 inhibitor, initially gaining traction for multiple myeloma (MM) treatment.
• Emerging clinical data suggests efficacy in other hematological malignancies.

Purpose of the Study:

• To review preclinical and clinical data on selinexor for non-MM hematological malignancies.
• To evaluate selinexor's efficacy as a single agent versus combination therapy.
• To guide the selection of selinexor-based induction chemotherapy regimens.

Main Methods:

• Systematic review of preclinical studies.
• Analysis of clinical trial data (Phase I, II, III).
• Evaluation of treatment outcomes and safety profiles.

Main Results:

• Selinexor demonstrates significant therapeutic effects in leukemia and lymphoma.
• Both monotherapy and combination regimens show promise.
• Specific efficacy data across different non-MM hematological cancers is presented.

Conclusions:

• Selinexor is a viable therapeutic option for non-MM hematological malignancies.
• Further research is warranted to optimize combination strategies.
• Personalized treatment approaches may enhance outcomes.